Rosiglitazone ảnh hưởng đến phân bố mô mỡ mà không có tác động xấu đến biến thiên nhịp tim ở bệnh nhân bệnh mạch vành kèm theo tiểu đường type 2

World-Health-Organization (2011) Global status report on noncommunicable diseases 2010

Despres JP, Lemieux I, Bergeron J et al (2008) Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28(6):1039–1049

Poirier P, Giles TD, Bray GA et al (2006) Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 26(5):968–976

Wang Y, Rimm EB, Stampfer MJ et al (2005) Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 81(3):555–563

Hillebrand S, Gast KB, de Mutsert R et al (2013) Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. Europace 15(5):742–749

Heart rate variability (1996) Standards of measurement, physiological interpretation and clinical use. Task force of the european society of cardiology and the north american society of pacing and electrophysiology. Circulation 93(5):1043–1065

Salamin G, Pelletier C, Poirier P et al (2013) Impact of visceral obesity on cardiac parasympathetic activity in type 2 diabetics after coronary artery bypass graft surgery. Obesity (Silver Spring) 21(8):1578–1585

Poliakova N, Despres JP, Bergeron J et al (2012) Influence of obesity indices, metabolic parameters and age on cardiac autonomic function in abdominally obese men. Metabolism 61(9):1270–1279

Saito I, Hitsumoto S, Maruyama K et al (2015) Heart rate variability, insulin resistance, and insulin sensitivity in japanese adults: the toon health study. J Epidemiol 25(9):583–591

Windham BG, Fumagalli S, Ble A et al (2012) The relationship between heart rate variability and adiposity differs for central and overall adiposity. J Obes 2012:149516

Shah P, Mudaliar S (2010) Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 9(2):347–354

Vasudevan AR, Balasubramanyam A (2004) Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 6(6):850–863

Bertrand OF, Poirier P, Rodes-Cabau J et al (2009) A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the vein-coronary atherosclerosis and rosiglitazone after bypass surgery (victory) trial. Can J Cardiol 25(9):509–515

Canadian Diabetes Association Clinical Practice Guidelines Expert C, Goldenberg R, Punthakee Z (2013) Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 37(Suppl 1):S8–S11

Pare A, Dumont M, Lemieux I et al (2001) Is the relationship between adipose tissue and waist girth altered by weight loss in obese men? Obes Res 9(9):526–534

Ferland M, Despres JP, Tremblay A et al (1989) Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 61(2):139–148

Mathieu P, Poirier P, Pibarot P et al (2009) Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 53(4):577–584

Neeland IJ, Ayers CR, Rohatgi AK et al (2013) Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 21(9):E439–E447

Straznicky NE, Grima MT, Sari CI et al (2014) A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome. J Clin Endocrinol Metab 99(9):E1701–E1707

Tchernof A, Despres JP (2013) Pathophysiology of human visceral obesity: an update. Physiol Rev 93(1):359–404

Lebovitz HE, Dole JF, Patwardhan R et al (2001) Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86(1):280–288

Diamant M, Heine RJ (2003) Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63(13):1373–1405

Jensen MD (1997) Lipolysis: contribution from regional fat. Annu Rev Nutr 17:127–139

Kahn CR, Chen L, Cohen SE (2000) Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106(11):1305–1307

Raskin P, Rappaport EB, Cole ST et al (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type ii diabetes. Diabetologia 43(3):278–284

Yamauchi T, Kamon J, Waki H et al (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (ppargamma) deficiency and ppargamma agonist improve insulin resistance. J Biol Chem 276(44):41245–41254

Goropashnaya AV, Herron J, Sexton M et al (2009) Relationships between plasma adiponectin and body fat distribution, insulin sensitivity, and plasma lipoproteins in alaskan yup’ik eskimos: the center for Alaska native health research study. Metabolism 58(1):22–29

Canale MP, Manca di Villahermosa S, Martino G et al (2013) Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Int J Endocrinol 2013:865965

Saijo Y, Kiyota N, Kawasaki Y et al (2004) Relationship between c-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes Obes Metab 6(4):249–258

Tuininga YS, van Veldhuisen DJ, Brouwer J et al (1994) Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br Heart J 72(6):509–513